1160502-41-9

Basic information

• Product Name: ethyl 2-(3-(3-bromophenyl)oxetan-3-yl)acetate
• Synonyms: ethyl 2-(3-(3-bromophenyl)oxetan-3-yl)acetate
• CAS NO: 1160502-41-9
• Molecular Weight: 299.164
• Mol File: 1160502-41-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: ethyl 2-(3-(3-bromophenyl)oxetan-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(3-(3-bromophenyl)oxetan-3-yl)acetate(1160502-41-9)
• EPA Substance Registry System: ethyl 2-(3-(3-bromophenyl)oxetan-3-yl)acetate(1160502-41-9)

Safety Data

• Hazardous Substances Data: 1160502-41-9(Hazardous Substances Data)

Upstream product

• 922500-91-2 ethyl 2-(oxetan-3-ylidene)acetate 
• 89598-96-9 (3-bromophenyl)boronic acid 

Downstream Products

• 1160502-42-0 [3-(3-bromophenyl)oxetan-3-yl]acetic acid 
• 1160501-81-4 (3-(3-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)oxetan-3-yl)methanamine 

Relevant articles and documents

UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION

Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells invivo, in vitro, or ex vivo.

INHIBITORS OF CBL-B AND METHODS OF USE THEREOF

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

[1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA

The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.